Of note, HER2DX was explored in 91 patients from the PAMELA phase II trial, where patients with early-stage HER2-positive breast cancer received neoadjuvant trastuzumab-lapatinib,10 indicating that HER2DX could predict pCR following dual HER2 blockade without chemotherapy. Here, ERBB2 is linked to breast carcinoma.